MedPath

Validation of the Turkish Translation of the London Speech Evaluation Scale

Completed
Conditions
Speech Intelligibility
Head and Neck Cancer
Speech Dysfunction
Speech Disorders
Speech
Interventions
Other: The speech records related to the reading document
Registration Number
NCT04690166
Lead Sponsor
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Brief Summary

Purpose of the study is the validation and cultual adaptation of the Turkish translation of the London Speech Evaluation Scale (LSE-T), so that it would be used as an assessment tool for Turkish head and neck cancer patients. There is no validated Turkish version of LSE to measure severity of perceptual speech in head and neck cancer patients.

Detailed Description

The speech function is a multidirectional process that depends on complex neuro-muscular network. The function can be evaluated using instrumental, such as voice analysis computer programmes, scales, or well structured questionnaires. There are many scales for assessment of perceptual speech but there is no validated for head and neck patients. The study will assess the construct validity and adaptation of the Turkish translation of Speech Specific Perceptual Speech Evaluation as known as London Speech Evaluation Scale. The investigators developed the Turkish translation of this scale (LSE-T), according to the cross-cultural adaptation guidelines. Two translators translated the LSE into Turkish and a native English language speaker reverse-translated it into English. The back translation was sent to the original author for proofreading. The LSE scale consisted of 6 parameters and 4 scores related with perceptual speech in head and neck cancer patients.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Able to speak, read, understand and write in Turkish
  • History of oral, orofarengeal cancer
  • Volunteers who accept the informed consent
Exclusion Criteria
  • Mental disorders
  • Cognitive limitations
  • Able not to speak, read, understand and write in Turkish
  • Underwent any surgery last six month
  • Permanent tracheostomy, total laryngectomy
  • Pregnancy
  • Out of age 18-70 years old
  • Adults who do not accept the informed consent.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Healty ControlThe speech records related to the reading documentIn outpatients clinic, the control group consists of 60 patients who have not speech and hear impairments. The participants will given the document consists that "bit, bet, but" words and also a brief part of "Diyet passage" who written by Omer Seyffettin. The speech record of patients who read to document, will evaluated by three judges (otorhinolaryngologist). Three judges will scoring to Turkish translation of London Speech Evaluation Scale (LSE-T), consists of 6 parameters. After the six weeks, the records were scored again as randomisely.
Cancer PatientsThe speech records related to the reading documentIn outpatients clinic, the first group consists of 60 head and neck cancer patients who were treated by ours. The participants will given the document consists that "bit, bet, but" words and also a brief part of "Diyet passage" who written by Omer Seyffettin. The speech record of patients who read to document, will evaluated by three judges (otorhinolaryngologist). Three judges will scoring to Turkish translation of London Speech Evaluation Scale (LSE-T), consists of 6 parameters. After the six weeks, the records were scored again as randomisely.
Primary Outcome Measures
NameTimeMethod
Validation of the Turkish Translation of London Speech Evaluation Scale6 weeks

Turkish Translation of London Speech Evaluation Scale consists of 6 parameters and 4 scores. The minimum score is 0 and maximum score is 24. The lower scores mean a better than high scores.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Prof Dr Cemil Tascioglu City Hospital

🇹🇷

Istanbul, Turkey

© Copyright 2025. All Rights Reserved by MedPath